Diplomat Pharmacy (DPLO) Releases FY18 Earnings Guidance

Diplomat Pharmacy (NYSE:DPLO) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $(0.10)-$0.03 for the period, compared to the Thomson Reuters consensus estimate of $0.83. The company issued revenue guidance of $5.5-5.7 billion, compared to the consensus revenue estimate of $5.64 billion.

Several research firms recently issued reports on DPLO. ValuEngine cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Tuesday. Robert W. Baird cut shares of Diplomat Pharmacy from a neutral rating to an underperform rating and decreased their target price for the company from $22.00 to $10.00 in a research note on Wednesday. Zacks Investment Research cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Tuesday, October 23rd. Finally, Wells Fargo & Co decreased their target price on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a market perform rating for the company in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $25.20.

NYSE:DPLO traded up $0.18 during trading hours on Thursday, reaching $14.98. 113,551 shares of the company were exchanged, compared to its average volume of 765,330. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.91. The stock has a market capitalization of $1.51 billion, a PE ratio of 17.83 and a beta of 0.95. Diplomat Pharmacy has a twelve month low of $13.31 and a twelve month high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.21). The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.33% and a net margin of 0.04%. The business’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.01 earnings per share. Research analysts forecast that Diplomat Pharmacy will post 0.83 earnings per share for the current year.

In other news, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total value of $1,104,575.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. Corporate insiders own 24.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/08/diplomat-pharmacy-dplo-releases-fy18-earnings-guidance.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: Why do corrections happen?

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply